Robert T O'donnell

Title(s)Professor Emeritus, Hematology and Oncology
SchoolUniversity of California, Davis
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. Am J Hematol. 2019 11; 94(11):E291-E294. Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA. PMID: 31379016.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    2. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2018 05; 81(5):957-963. El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H, Lenz HJ, Gandara DR. PMID: 29520435; PMCID: PMC6330274.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    3. A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation. PLoS One. 2018; 13(1):e0190860. Barisone GA, O'Donnell RT, Ma Y, Abuhay MW, Lundeberg K, Gowda S, Tuscano JM. PMID: 29304125; PMCID: PMC5755921.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    4. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity. Cancer Immunol Immunother. 2016 10; 65(10):1169-75. Abuhay M, Kato J, Tuscano E, Barisone GA, Sidhu RS, O'Donnell RT, Tuscano JM. PMID: 27506529; PMCID: PMC7643839.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    5. Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7. Leuk Res. 2014 Nov; 38(11):1320-6. Kong Y, Barisone GA, Abuhay M, O'Donnell RT, Buksh Z, Yousefian F, Tuscano JM. PMID: 25241275.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    6. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014 May; 165(3):375-81. Tuscano JM, Dutia M, Chee K, Brunson A, Reed-Pease C, Abedi M, Welborn J, O'Donnell RT. PMID: 24606326.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    7. Targeting CD22 in B-cell malignancies: current status and clinical outlook. BioDrugs. 2013 Aug; 27(4):293-304. Sullivan-Chang L, O'Donnell RT, Tuscano JM. PMID: 23696252.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimals
    8. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst. 2013 Jul 03; 105(13):954-9. Abrams JS, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, DiPiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O'Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH. PMID: 23776198; PMCID: PMC3699438.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    9. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia. Leuk Res. 2013 Jan; 37(1):83-8. Kato J, Satake N, O'Donnell RT, Abuhay M, Lewis C, Tuscano JM. PMID: 23040543.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    10. CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. Cancer Res. 2012 Nov 01; 72(21):5556-65. Tuscano JM, Kato J, Pearson D, Xiong C, Newell L, Ma Y, Gandara DR, O'Donnell RT. PMID: 22986740.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    11. Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma. Mol Pharm. 2012 Jun 04; 9(6):1727-35. Kato J, Li Y, Xiao K, Lee JS, Luo J, Tuscano JM, O'Donnell RT, Lam KS. PMID: 22530955; PMCID: PMC4560237.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    12. The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner. J Hematol Oncol. 2011 Dec 01; 4:49. Martin SM, Churchill E, McKnight H, Mahaffey CM, Ma Y, O'Donnell RT, Tuscano JM. PMID: 22128838; PMCID: PMC3287147.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    13. The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone. Cancer Immunol Immunother. 2011 Jun; 60(6):771-80. Tuscano JM, Ma Y, Martin SM, Kato J, O'Donnell RT. PMID: 21347809; PMCID: PMC3098984.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    14. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res. 2010 May 15; 16(10):2760-8. Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. PMID: 20460479.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    15. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts. Cancer Immunol Immunother. 2009 Dec; 58(12):2051-8. O'Donnell RT, Ma Y, McKnight HC, Pearson D, Tuscano JM. PMID: 19437017; PMCID: PMC2749165.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    16. Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD). Invest New Drugs. 2010 Jun; 28(3):260-7. O'Donnell RT, Martin SM, Ma Y, Zamboni WC, Tuscano JM. PMID: 19306119; PMCID: PMC2850518.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    17. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy. Cancer Immunol Immunother. 2009 Oct; 58(10):1715-22. O'Donnell RT, Pearson D, McKnight HC, Ma YP, Tuscano JM. PMID: 19294384.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    18. Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells. Leuk Res. 2009 Jul; 33(7):964-9. O'Donnell RT, Pearson D, McKnight HC, Ma YP, Tuscano JM. PMID: 19237192.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    19. Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts. Mol Imaging Biol. 2009 Mar-Apr; 11(2):79-87. Martin SM, O'Donnell RT, Kukis DL, Abbey CK, McKnight H, Sutcliffe JL, Tuscano JM. PMID: 18949521.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    20. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 2007 Aug; 22(4):521-30. Schillaci O, DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, O'Donnell RT, Lamborn KR. PMID: 17803447.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    21. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007 Apr; 106(4):601-8. Semrad TJ, O'Donnell R, Wun T, Chew H, Harvey D, Zhou H, White RH. PMID: 17432710.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    22. Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 15; 66(4):1192-8. Lehmann J, DeNardo GL, Yuan A, Shen S, O'Donnell RT, Richman CM, DeNardo SJ. PMID: 16965873.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. Nuclear localizing sequences: an innovative way to improve targeted radiotherapy. J Nucl Med. 2006 May; 47(5):738-9. O'Donnell RT. PMID: 16644741.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    24. Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody. Cancer Biother Radiopharm. 2005 Dec; 20(6):662-70. Shen S, DeNardo GL, Yuan A, Hartmann-Siantar C, O'Donnell RT, DeNardo SJ. PMID: 16398618.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    25. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 2):7187s-7194s. DeNardo SJ, Richman CM, Albrecht H, Burke PA, Natarajan A, Yuan A, Gregg JP, O'Donnell RT, DeNardo GL. PMID: 16203820.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    26. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res. 2005 Aug 15; 11(16):5920-7. Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL. PMID: 16115934.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCTClinical Trials
    27. Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry. J Nucl Med. 2005 Jun; 46(6):1034-41. Shen S, DeNardo SJ, Richman CM, Yuan A, Siantar CH, O'Donnell RT, Kroger LA, DeNardo GL. PMID: 15937317.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    28. Secondary supratentorial primitive neuroectodermal tumor following irradiation in a patient with low-grade astrocytoma. AJNR Am J Neuroradiol. 2005 Jan; 26(1):160-2. Chen AY, Lee H, Hartman J, Greco C, Ryu JK, O'Donnell R, Boggan J. PMID: 15661719; PMCID: PMC7975032.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. PMID: 15530258.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    30. Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 2):3854S-64S. DeNardo SJ, Yao Z, Lam KS, Song A, Burke PA, Mirick GR, Lamborn KR, O'Donnell RT, DeNardo GL. PMID: 14506183.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    31. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 2):3938S-44S. DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL. PMID: 14506192.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    32. Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs. Cancer Biother Radiopharm. 2003 Apr; 18(2):231-7. DeNardo G, Yuan A, Goldstein D, Richman C, O'Donnell R, Shen S, Hartmann Siantar C, DeNardo S. PMID: 12804049.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood. 2003 May 01; 101(9):3641-7. Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL. PMID: 12511412.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    34. Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest. 2003; 21(1):1-6. Perez EA, Gandara DR, Edelman MJ, O'Donnell R, Lauder IJ, DeGregorio M. PMID: 12643003.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    35. Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation. Transfusion. 2002 Dec; 42(12):1567-72. Hutchinson K, Kopko PM, Muto KN, Tuscano J, O'Donnell RT, Holland PV, Richman C, Paglieroni TG, Wun T. PMID: 12473136.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    36. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate. 2002 Jan 01; 50(1):27-37. O'Donnell RT, DeNardo SJ, Miers LA, Lamborn KR, Kukis DL, DeNardo GL, Meyers FJ. PMID: 11757033.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    37. Metabolite production in patients with lymphoma after radiometal-labeled antibody administration. J Nucl Med. 2001 Sep; 42(9):1324-33. DeNardo GL, DeNardo SJ, Kukis DL, O'Donnell RT, Shen S, Mirick GR, Meares CF. PMID: 11535720.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res. 2001 Jun; 7(6):1561-8. O'Donnell RT, DeNardo SJ, Yuan A, Shen S, Richman CM, Lara PN, Griffith IJ, Goldstein DS, Kukis DL, Martinez GS, Mirick GR, DeNardo GL, Meyers FJ. PMID: 11410491.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCTClinical Trials
    39. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001 Mar 15; 19(6):1728-33. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. PMID: 11251003.
      View in: PubMed   Mentions: 246     Fields:    Translation:Humans
    40. Radiolabeled anti-lymphoma antibodies. Cancer Chemother Biol Response Modif. 2001; 19:297-308. DeNardo GL, O'Donnell RT, DeNardo SJ. PMID: 11686019.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    41. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. Clin Lymphoma. 2000 Sep; 1(2):118-26. DeNardo GL, DeNardo SJ, O'Donnell RT, Kroger LA, Kukis DL, Meares CF, Goldstein DS, Shen S. PMID: 11707820.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    42. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. Anticancer Res. 2000 Sep-Oct; 20(5C):3647-55. O'Donnell RT, Shen S, Denardo SJ, Wun T, Kukis DL, Goldstein DS, Denardo GL. PMID: 11268433.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCTClinical Trials
    43. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice. Prostate. 2000 Aug 01; 44(3):187-92. O'Donnell RT, DeNardo SJ, DeNardo GL, Miers L, Lamborn KR, Kukis DL, Meyers FJ. PMID: 10906734.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    44. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med. 2000 May; 41(5):952-8. DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, Kukis DL, DeNardo SJ. PMID: 10809213.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm. 2000 Feb; 15(1):71-9. DeNardo SJ, Burke PA, Leigh BR, O'Donnell RT, Miers LA, Kroger LA, Goodman SL, Matzku S, Jonczyk A, Lamborn KR, DeNardo GL. PMID: 10740655.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    46. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med. 1999 Dec; 40(12):2014-20. O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Carr CE, Mirick GR, DeNardo SJ. PMID: 10616879.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    47. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med. 1999 Dec; 40(12):2102-6. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. PMID: 10616892.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    48. Strategies for developing effective radioimmunotherapy for solid tumors. Clin Cancer Res. 1999 Oct; 5(10 Suppl):3219s-3223s. DeNardo GL, O'Donnell RT, Kroger LA, Richman CM, Goldstein DS, Shen S, DeNardo SJ. PMID: 10541367.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    49. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A. Clin Cancer Res. 1999 Oct; 5(10 Suppl):3243s-3248s. Richman CM, DeNardo SJ, O'Donnell RT, Goldstein DS, Shen S, Kukis DL, Kroger LA, Yuan A, Boniface GR, Griffith IJ, DeNardo GL. PMID: 10541370.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    50. Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. Nucl Med Biol. 1999 Oct; 26(7):841-5. Mirick GR, O'Donnell RT, DeNardo SJ, Shen S, Meares CF, DeNardo GL. PMID: 10628566.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    51. Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage. Cancer Biother Radiopharm. 1999 Oct; 14(5):363-9. Kukis DL, DeNardo SJ, Mills SL, Shen S, O'Donnell RT, DeNardo GL. PMID: 10850321.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    52. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma. Clin Cancer Res. 1999 Oct; 5(10 Suppl):3330s-3336s. O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Mirick GR, DeNardo SJ. PMID: 10541382.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCTClinical Trials
    53. Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma. Cancer Biother Radiopharm. 1999 Jun; 14(3):167-76. O'Donnell RT, Leigh BR, Christensen SD, Goldstein DS, Kukis DL, Shen S, Yuan A, DeNardo DA, Kroger LA, DeNardo GL. PMID: 10850301.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    54. Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy. Cancer Biother Radiopharm. 1999 Apr; 14(2):113-9. Leigh BR, Burke PA, Hong AM, O'Donnell RT, Howell LP, Miers LA, DeNardo GL, DeNardo SJ. PMID: 10850294.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    55. Milestones in the development of Lym-1 therapy. Hybridoma. 1999 Feb; 18(1):1-11. DeNardo GL, O'Donnell RT, Rose LM, Mirick GR, Kroger LA, DeNardo SJ. PMID: 10211782.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCTClinical Trials
    56. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J Nucl Med. 1998 Dec; 39(12):2105-10. Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF. PMID: 9867151.
      View in: PubMed   Mentions: 11     Fields:    Translation:Cells
    57. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts. Cancer Biother Radiopharm. 1998 Oct; 13(5):351-61. O'Donnell RT, DeNardo SJ, Miers LA, Kukis DL, Mirick GR, Kroger LA, DeNardo GL. PMID: 10851425.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    58. L6 monoclonal antibody binds prostate cancer. Prostate. 1998 Oct 01; 37(2):91-7. O'Donnell RT, DeNardo SJ, Shi XB, Mirick GR, DeNardo GL, Kroger LA, Meyers FJ. PMID: 9759703.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    59. A revolution in the treatment of non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 1998 Aug; 13(4):213-23. DeNardo GL, O'Donnell RT, Oldham RK, DeNardo SJ. PMID: 10850358.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    60. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anticancer Res. 1998 Jul-Aug; 18(4B):2779-88. Denardo GL, Denardo SJ, Kukis DL, O'Donnell RT, Shen S, Goldstein DS, Kroger LA, Salako Q, Denardo DA, Mirick GR, Mausner LF, Srivastava SC, Meares CF. PMID: 9713461.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    61. A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy. J Nucl Med. 1998 Jul; 39(7):1223-9. Shen S, DeNardo GL, Jones TD, Wilder RB, O'Donnell RT, DeNardo SJ. PMID: 9669399.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    62. Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations. J Nucl Med. 1998 Apr; 39(4):667-70. Salako QA, O'Donnell RT, DeNardo SJ. PMID: 9544679.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    63. Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies. Cancer. 1997 Dec 15; 80(12 Suppl):2553-7. Shen S, DeNardo GL, O'Donnell RT, Yuan A, DeNardo DA, DeNardo SJ. PMID: 9406709.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    64. Imaging for improved prediction of myelotoxicity after radioimmunotherapy. Cancer. 1997 Dec 15; 80(12 Suppl):2558-66. DeNardo DA, DeNardo GL, O'Donnell RT, Lim SM, Shen S, Yuan A, DeNardo SJ. PMID: 9406710.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    65. Peripheral blood stem cell mobilization for hematopoietic support of radioimmunotherapy in patients with breast carcinoma. Cancer. 1997 Dec 15; 80(12 Suppl):2728-32. Richman CM, Schuermann TC, Wun T, Malik R, O'Donnell RT, DeNardo GL, DeNardo SJ. PMID: 9406731.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    66. Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2. Cancer. 1997 Dec 15; 80(12 Suppl):2576-82. DeNardo GL, Kukis DL, DeNardo SJ, Shen S, Mausner LF, O'Donnell RT, Lamborn KR, Meyers FJ, Srivastava SC, Miers LA. PMID: 9406712.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    67. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer. 1997 Dec 15; 80(12 Suppl):2583-90. DeNardo SJ, Kroger LA, Lamborn KR, Miers LA, O'Donnell RT, Kukis DL, Richman CM, DeNardo GL. PMID: 9406713.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    68. Prediction of myelotoxicity using semi-quantitative marrow image scores. J Nucl Med. 1997 Nov; 38(11):1749-53. Lim S, DeNardo GL, DeNardo DA, O'Donnell RT, Yuan A, DeNardo SJ. PMID: 9374345.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    69. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med. 1997 Sep; 38(9):1374-8. Lim SM, DeNardo GL, DeNardo DA, Shen S, Yuan A, O'Donnell RT, DeNardo SJ. PMID: 9293790.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    70. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med. 1997 Aug; 38(8):1180-5. DeNardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL, DeNardo GL. PMID: 9255145.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    71. Practical determination of organ S values for individual patients for therapy. Nucl Med Biol. 1997 Jul; 24(5):447-9. Shen S, DeNardo GL, Macey DJ, O'Donnell RT, Yuan A, DeNardo DA, DeNardo SJ. PMID: 9290081.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    72. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res. 1997 May-Jun; 17(3B):1745-51. Denardo SJ, O'Grady LF, Richman CM, Goldstein DS, O'Donnell RT, Denardo DA, Kroger LA, Lamborn KR, Hellström KE, Hellström I, Denardo GL. PMID: 9179228.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCTClinical Trials
    73. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A. 1997 Apr 15; 94(8):4000-4. DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL. PMID: 9108094; PMCID: PMC20557.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimals
    74. Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. Am J Hematol. 1997 Apr; 54(4):329-31. Edelman MJ, O'Donnell RT, Meadows I. PMID: 9092691.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    75. Potential use of amino acid cocktails to reduce renal tubular reabsorption of radioconjugates. J Nucl Med. 1996 May; 37(5):837-8. DeNardo SJ, O'Donnell RT, DeNardo GL. PMID: 8965156.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    76. Antibody responses to macrocycles in lymphoma. J Nucl Med. 1996 Mar; 37(3):451-6. DeNardo GL, Mirick GR, Kroger LA, O'Donnell RT, Meares CF, DeNardo SJ. PMID: 8772643.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    77. Palliative embolization of fibrosarcoma for control of tumor-induced hypoglycemia. Cardiovasc Intervent Radiol. 1995 Jul-Aug; 18(4):255-8. Lengle SJ, Hecht ST, Link DP, O'Donnell R. PMID: 8581908.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    78. A phase II trial of concomitant interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in patients with advanced renal cell carcinoma. J Immunother Emphasis Tumor Immunol. 1995 Jan; 17(1):58-61. O'Donnell RT, Dea G, Meyers FJ. PMID: 7728306.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    79. Vincristine for thrombocytopenic purpura. Lancet. 1991 Feb 09; 337(8737):377-8. Welborn JL, O'Donnell R, Hsieh T, Eatherton J, Aspry K. PMID: 1671287.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    80. Isolation of canine neutrophil plasma membranes. J Leukoc Biol. 1985 Sep; 38(3):353-68. O'Donnell RT, Andersen BR. PMID: 2993461.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    81. Canine neutrophil plasma membrane markers. Biochim Biophys Acta. 1985 Apr 11; 814(2):307-12. O'Donnell RT, Andersen BR. PMID: 2983765.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    82. Characterization of canine neutrophil granules. Infect Immun. 1982 Oct; 38(1):351-9. O'Donnell RT, Andersen BR. PMID: 6292095; PMCID: PMC347737.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    83. Gaseous contaminants in sterilized evacuated blood collection tubes. Clin Chem. 1982 Jun; 28(6):1406. Jensen WE, O'Donnell RT, Rosenberg IH, Karlin DA, Jones RD. PMID: 7074960.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    84. Effect of dioctyl sodium sulfosuccinate feeding on rat colorectal 1,2-dimethylhydrazine carcinogenesis. J Natl Cancer Inst. 1980 Apr; 64(4):791-3. Karlin DA, O'Donnell RT, Jensen WE. PMID: 6154162.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    With one click, see people who:

    Mentor

    Offer Student Projects

    Run Clinical Trials

    See more options in the Advanced Search tab

    Robert's Networks
    Concepts (367)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (31)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UC Davis Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California